Scientists at Ferring develop biomarker to measure gut bacteria impacted by antibiotic treatments
1月
9日
source: dreamstime.com
The Ferring MHI-A algorithm differentiates post-antibiotic dysbiosis from healthy microbiota in the gut associated with healthy Bacteroidia and Clostridia, versus potentially harmful species such as Gammaproteobacteria and Bacilli.
Researchers at Ferring say MHI-A is a useful for rank-ordering the microbiota-disrupting effects of antibiotics and a measure of microbiota restoration. Ken Blount, Chief Scientific Officer, Rebiotix, Vice President Microbiome Research, Ferring Pharmaceuticals, is quoted by Business Wire as saying, “This biomarker provides a concise metric for assessing the complex changes in the microbiome of trial participants pre- to post-treatment.”
https://www.frontiersin.org/articles/10.3389/fmicb.2021.781275
https://www.businesswire.com/news/home/20220107005052/en/Frontiers-in-Microbiology-Publishes-Article-Detailing-Novel-Microbiome-based-Biomarker-of-Post-Antibiotic-Disruptions-in-Gut-Microbiota
シェア
神谷保険